At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 226 enrolled
Drug / intervention
Ginkgo Biloba +1 moredrug
Likely dose
Ginkgo Biloba 120 mg per day (60 mg twice daily)AI-extracted
Key inclusion· 7
- ✓Newly diagnosed breast cancer
- ✓Planned to receive standard adjuvant chemotherapy with or without a taxane
- ✓Age 18 or older
- ✓Female
Key exclusion· 13
- ✕Diabetes
- ✕Dementia
- ✕Psychiatric disorder diagnosed within the past 5 years that would preclude study compliance
- ✕Significant comorbidity
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Use of Ginkgo Biloba For The Prevention Of Chemotherapy-Related Cognitive Dysfunction
In Brief
A Phase 3 clinical trial evaluating Ginkgo Biloba and Placebo for Breast Cancer and Neurotoxicity. Completed, enrolled 226 participants across 175 sites.
Detailed Summary
RATIONALE: Chemotherapy may cause memory loss, attention loss, and other problems that make it difficult for patients to think clearly. EGb761 may help maintain mental clarity in patients undergoing chemotherapy. PURPOSE: Randomized clinical trial to study the effectiveness of EGb761 in preventing loss of mental clarity in women who are receiving chemotherapy for newly diagnosed breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Neurotoxicity
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2002
First PostedJan 2003
Primary CompletionOct 2006
Study CompletionApr 2015
TodayJul 2026
First PostedJan 27, 2003
Enrollment StartDec 1, 2002
Primary CompletionOct 1, 2006
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 23.4 years ago
Interventions
Ginkgo Bilobadrug
Patients will take 120 mg per day (60 mg BID)
Placeboother
Patients will take 1 tablet BID